rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Vanda Pharmaceuticals Inc.

VNDA · Nasdaq

Health CarePharmaceuticalsNot moving yet

VNDA stood above a rising 150-day average in 25 of the last 52 weekly readings, and has been out of that trend for the last 24 weeks. It is 30.9% below that average now. Pharmaceuticals: 32% of its 74 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 24
Industry in uptrend
32% -7 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$5.6M
Officials’ trades on record
0
Institutions holding
159 (+1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 25 of 52 weeks.

20 Apr – 19 Oct
26%34%43%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$5.0M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months6
Buyers · sellers0 · 6
WhoDidSharesTraded
Mihael Hristos PolymeropoulosPresident and CEOsold156,235at $8.172 Mar 2026filed 4 Mar 2026
Gunther BirznieksSVP, Business Developmentsold42,431at $8.272 Mar 2026filed 4 Mar 2026
Timothy WilliamsSVP & General Counselsold42,434at $8.272 Mar 2026filed 4 Mar 2026
Joakim WijkstromSVP, Chief Marketing Officersold30,800at $8.272 Mar 2026filed 4 Mar 2026
Kevin Patrick MoranSVP, CFO & Treasurersold42,442at $8.272 Mar 2026filed 4 Mar 2026
Tage HonoreDirectorsold30,000at $8.0323 Feb 2026filed 24 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders159+1 on the quarter
New · exited27 · 26
Reported value$287.2M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20267,653,737$46.8M+377,749+5.2%
STATE STREET CORPadded · filed 7 Aug 20263,516,405$21.5M+500,843+16.6%
AQR CAPITAL MANAGEMENT LLCadded · filed 14 Aug 20263,497,695$21.4M+1,894,119+118.1%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 20263,441,361$21.1M-318,198−8.5%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,524,040$15.4M+42,549+1.7%
AIGH Capital Management LLCreduced · filed 7 Aug 20262,044,169$12.5M-705,831−25.7%
DIMENSIONAL FUND ADVISORS LPreduced · filed 11 Aug 20261,727,349$10.6M-44,244−2.5%
MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 20261,602,813$9.8M-278,188−14.8%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,483,787$9.1M+40,822+2.8%
TWO SIGMA INVESTMENTS, LPreduced · filed 14 Aug 20261,349,072$8.3M-49,129−3.5%
31 Mar 2023 – 30 Jun 2026
123141158Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Anne Sempowski Ward Company insiderDirector · last 4 Jun 20260 · 0
Charles Cliff Duncan Company insiderDirector · last 4 Jun 20260 · 0
Daniel Patrick McGuire Company insiderSVP, GC and Secretary · last 4 Jun 20260 · 0
Phaedra Chrousos Company insiderDirector · last 4 Jun 20260 · 1
Richard W. Dugan Company insiderDirector · last 4 Jun 20260 · 5
Stephen Ray Mitchell Company insiderDirector · last 4 Jun 20260 · 6
Tage Honore Company insiderDirector · last 4 Jun 20260 · 1
Gunther Birznieks Company insiderSVP, Business Development · last 2 Mar 20260 · 18
Joakim Wijkstrom Company insiderSVP, Chief Marketing Officer · last 2 Mar 20260 · 11
Kevin Patrick Moran Company insiderSVP, CFO & Treasurer · last 2 Mar 20261 · 15
Mihael Hristos Polymeropoulos Company insiderPresident and CEO · last 2 Mar 202617 · 54
Timothy Williams Company insiderSVP & General Counsel · last 2 Mar 20260 · 17

Same industry

ABBV AbbVieLeading+19%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-70.0%
Free cash flow marginFY 2025 · to 31 Dec 2025-51.1%
Return on capital employedFY 2025 · to 31 Dec 2025-44.0%
Research spendFY 2025 · to 31 Dec 202550.6%
Share count trendFY 2025 · to 5 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$84.9M
Free cash flowFY 2025 · to 31 Dec 2025−$110.4M

Analyst forecasts

No analyst forecasts yet.